Capital Square’s Gilead Sciences GILD Stock Holding History

Capital Square’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$203K	Buy	+1,360	New	+$191K	0.09%	233
2022 Q1	–	Sell	-3,363	Closed	-$242K	–	160
2021 Q4	$242K	Sell	3,363 -1	-0%	-$69	0.17%	131
2021 Q3	$230K	Hold	3,364	–	–	0.16%	138
2021 Q2	$230K	Sell	3,364 -114	-3%	-$7.61K	0.17%	131
2021 Q1	$226K	Hold	3,478	–	–	0.17%	132
2020 Q4	$202K	Hold	3,478	–	–	0.17%	138
2020 Q3	$219K	Sell	3,478 -204	-6%	-$14.1K	0.23%	117
2020 Q2	$283K	Sell	3,682 -198	-5%	-$15.2K	0.3%	100
2020 Q1	$290K	Buy	3,880 +87	+2%	+$6.01K	0.34%	87
2019 Q4	$246K	Buy	+3,793	New	+$247K	0.23%	106

Other funds holding GILD

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Capital Square's GILD Position: Q3 2026 in Review

Capital Square opened a new position in Gilead Sciences (GILD) in Q3 2026: 1,360 shares worth $203K. The stake represents 0.09% of the portfolio and ranks #233 among its holdings. This is a return to the name: Capital Square previously reported a position in GILD as recently as Q4 2021.

Capital Square first reported a position in GILD in Q4 2019 and has held it in 10 quarters since. The position peaked at $290K in Q1 2020. 1,637 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

Capital Square held 1,360 shares of Gilead Sciences worth $203K as of Q3 2026.
Gilead Sciences was a new Capital Square position in Q3 2026.
Gilead Sciences made up 0.09% of Capital Square's portfolio in Q3 2026, its #233 holding.
Capital Square first reported a position in Gilead Sciences in Q4 2019 and has held it in 10 quarters since.
Capital Square's Gilead Sciences position peaked at $290K in Q1 2020.
1,637 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Capital Square's 13F filing for Q3 2026, filed 19 Oct 2026.